TriReme CE marks Antares coronary stent system
This article was originally published in Clinica
TriReme Medical has CE marked its Antares coronary stent system, which is designed for use at or near coronary bifurcations, for sale in Europe. Antares fits all classes of bifurcation lesions, irrespective of the size and angle of the side-branch, the Pleasanton, California firm says. It can be delivered and deployed in a single step while maintaining access to the side-branch, meaning the physician can deploy a second stent in the side-branch if necessary. TriReme claims it could be used in a quarter of the 2.2 million angioplasty procedures performed annually worldwide. The system is not yet approved in the US.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.